

IMPORTANT PRESCRIBING INFORMATION**Important update for Toujeo® (insulin glargine 300 units/ml, solution for injection) to ensure its correct dosing prescription**

Dear Healthcare Professional,

The purpose of this letter is to give important information for prescriptions of Toujeo® (insulin glargine 300 units/ml) for the treatment of diabetes mellitus in adults to avoid medication errors that may potentially lead to dysglycaemia when switching to or from Toujeo® (insulin glargine 300 units/ml).

Summary

- Toujeo® (insulin glargine 300 units/ml) is available in two different presentations: Toujeo® **SoloStar®** (1.5 ml prefilled pen/450 units) and Toujeo® **DoubleStar™** (3 ml prefilled pen/900 units). **The dose increment in Toujeo® SoloStar® is 1 unit and the dose increment in Toujeo® DoubleStar™ is 2 units.**
- **Attached, you will find educational materials aimed at increasing awareness of the following key points:**
 - **Insulin glargine 100 units/ml and Toujeo® (insulin glargine 300 units/ml) are not bioequivalent and are therefore not interchangeable** without dose adjustment.
 - Dose adjustment may be needed when patients are switched to an insulin with a different strength.

Educational leaflets for patients are included with this correspondence for distribution to all patients treated with Toujeo®.

Information in this communication has been agreed with the Medicines and Healthcare products Regulatory Agency (MHRA).

For additional information

If you have any questions, or if you require additional copies of these educational materials, please contact Medical Information at Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK - Tel: 0845 372 7101, Email: uk-medicalinformation@sanofi.com

Yours sincerely,

Henrik Schou

Associate Director of Medical Affairs
Diabetes Medical Franchise, Sanofi UK

Enclosed: Toujeo guide for healthcare professionals and guide for patients.

SAGB.TJO.19.05.0885

VV-REG-0758337-1.0
Doc. No. 3701.0
May 2019